Glen Eagle Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $78.4K | Buy |
563
+94
| +20% | +$13.2K | 0.01% | 370 |
|
|
2025
Q4 | $57.5K | Buy |
469
+41
| +10% | +$4.98K | 0.01% | 421 |
|
|
2025
Q3 | $47.5K | Buy |
428
+43
| +11% | +$4.89K | 0.01% | 463 |
|
|
2025
Q2 | $42.7K | Hold |
385
| – | – | 0.01% | 448 |
|
|
2025
Q1 | $43.2K | Hold |
385
| – | – | 0.01% | 438 |
|
|
2024
Q4 | $35.6K | Hold |
385
| – | – | 0.01% | 475 |
|
|
2024
Q3 | $32.3K | Sell |
385
-174
| -31% | -$13.3K | 0.01% | 498 |
|
|
2024
Q2 | $38.4K | Sell |
559
-61
| -10% | -$4.07K | 0.01% | 445 |
|
|
2024
Q1 | $45.4K | Sell |
620
-89
| -13% | -$6.84K | 0.01% | 422 |
|
|
2023
Q4 | $57.4K | Buy |
709
+2
| +0.3% | +$156 | 0.01% | 368 |
|
|
2023
Q3 | $53K | Hold |
707
| – | – | 0.01% | 369 |
|
|
2023
Q2 | $54.4K | Sell |
707
-63
| -8% | -$5.03K | 0.01% | 364 |
|
|
2023
Q1 | $63.9K | Sell |
770
-103
| -12% | -$8.53K | 0.02% | 343 |
|
|
2022
Q4 | $75K | Buy |
873
+1
| +0.1% | +$79 | 0.02% | 313 |
|
|
2022
Q3 | $53.8K | Buy |
872
+1
| +0.1% | +$63 | 0.02% | 341 |
|
|
2022
Q2 | $53.8K | Sell |
871
-53
| -6% | -$3.28K | 0.01% | 353 |
|
|
2022
Q1 | $54.9K | Buy |
924
+2
| +0.2% | +$128 | 0.01% | 363 |
|
|
2021
Q4 | $67K | Sell |
922
-2,124
| -70% | -$146K | 0.02% | 334 |
|
|
2021
Q3 | $213K | Sell |
3,046
-91
| -3% | -$6.39K | 0.06% | 205 |
|
|
2021
Q2 | $216K | Buy |
3,137
+96
| +3% | +$6.41K | 0.07% | 201 |
|
|
2021
Q1 | $197K | Sell |
3,041
-330
| -10% | -$21.3K | 0.07% | 196 |
|
|
2020
Q4 | $196K | Sell |
3,371
-451
| -12% | -$27.2K | 0.08% | 175 |
|
|
2020
Q3 | $242K | Buy |
3,822
+16
| +0.4% | +$1.11K | 0.11% | 140 |
|
|
2020
Q2 | $293K | Buy |
3,806
+812
| +27% | +$62.2K | 0.15% | 117 |
|
|
2020
Q1 | $224K | Buy |
2,994
+1,532
| +105% | +$106K | 0.16% | 120 |
|
|
2019
Q4 | $95K | Buy |
1,462
+451
| +45% | +$29.4K | 0.05% | 229 |
|
|
2019
Q3 | $64.1K | Buy |
1,011
+1
| +0.1% | +$65 | 0.04% | 256 |
|
|
2019
Q2 | $68.2K | Sell |
1,010
-374
| -27% | -$24.6K | 0.05% | 244 |
|
|
2019
Q1 | $90K | Buy |
1,384
+31
| +2% | +$2.06K | 0.07% | 205 |
|
|
2018
Q4 | $84.6K | Sell |
1,353
-59
| -4% | -$4.12K | 0.07% | 196 |
|
|
2018
Q3 | $109K | Buy |
1,412
+161
| +13% | +$12.2K | 0.08% | 195 |
|
|
2018
Q2 | $88.6K | Buy |
1,251
+287
| +30% | +$20.3K | 0.07% | 202 |
|
|
2018
Q1 | $72.7K | Buy |
964
+185
| +24% | +$14.7K | 0.06% | 215 |
|
|
2017
Q4 | $55.8K | Buy |
779
+1
| +0.1% | +$76 | 0.05% | 234 |
|
|
2017
Q3 | $63K | Sell |
778
-76
| -9% | -$5.81K | 0.06% | 219 |
|
|
2017
Q2 | $60.5K | Sell |
854
-1,747
| -67% | -$116K | 0.05% | 203 |
|
|
2017
Q1 | $176K | Sell |
2,601
-2,152
| -45% | -$151K | 0.15% | 132 |
|
|
2016
Q4 | $340K | Buy |
+4,753
| New | +$353K | 0.31% | 88 |
|
Other funds holding GILD
VCM
VPM
Glen Eagle Advisors's GILD Position: Q1 2026 in Review
Glen Eagle Advisors increased its Gilead Sciences (GILD) stake by 20% in Q1 2026, buying an estimated $13.2K and bringing the position to 563 shares worth $78.4K. The position accounts for 0.01% of the portfolio, ranked #370.
Glen Eagle Advisors first reported a position in GILD in Q4 2016 and has held it in 38 quarters since. The position peaked at $340K in Q4 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Glen Eagle Advisors held 563 shares of Gilead Sciences worth $78.4K as of Q1 2026.
- Glen Eagle Advisors bought 94 Gilead Sciences shares in Q1 2026, an estimated $13.2K.
- Gilead Sciences made up 0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #370 holding.
- Glen Eagle Advisors first reported a position in Gilead Sciences in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Gilead Sciences position peaked at $340K in Q4 2016.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.